VINC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VINC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vincerx Pharma's annualized ROCE % for the quarter that ended in Mar. 2024 was -458.04%.
The historical data trend for Vincerx Pharma's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vincerx Pharma Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
ROCE % | - | -84.58 | -97.04 | -89.31 | -135.82 |
Vincerx Pharma Quarterly Data | |||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROCE % | Get a 7-Day Free Trial | -141.90 | -148.41 | -189.53 | -147.34 | -458.04 |
Vincerx Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -42.609 | / | ( ( (59.286 - 9.156) | + | (18.217 - 5.605) ) | / 2 ) | |
= | -42.609 | / | ( (50.13 | + | 12.612) | / 2 ) | |
= | -42.609 | / | 31.371 | ||||
= | -135.82 % |
Vincerx Pharma's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -29.912 | / | ( ( (18.217 - 5.605) | + | (11.083 - 10.634) ) | / 2 ) | |
= | -29.912 | / | ( ( 12.612 | + | 0.449 ) | / 2 ) | |
= | -29.912 | / | 6.5305 | ||||
= | -458.04 % |
(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vincerx Pharma (NAS:VINC) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Vincerx Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander A. Seelenberger | officer: Chief Financial Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Raquel E. Izumi | director, 10 percent owner, officer: Chief Operations Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Ahmed Md Hamdy | director, 10 percent owner, officer: President and CEO | 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Tom C Thomas | officer: See Remarks | 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030 |
Christopher P. Lowe | director | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
Laura I. Bushnell | director | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Rubric Capital Management Lp | 10 percent owner | 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
David Efraim Rosen | 10 percent owner | 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
Sooin Hwang | officer: Chief Business Officer | 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306 |
Xiaoming Zhang | officer: Chief Technology Officer | 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306 |
Ruth E. Stevens | director | 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306 |
Garban Hermes De Jesus | officer: Chief Medical Officer | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
John C. Byrd | 10 percent owner | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
Brian Druker | director | ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
John H. Lee | director | 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054 |
From GuruFocus
By sperokesalga sperokesalga • 04-17-2023
By Value_Insider Value_Insider • 12-11-2022
By Marketwired • 08-22-2023
By Value_Insider Value_Insider • 11-10-2022
By GlobeNewswire • 01-07-2024
By Marketwired • 11-02-2023
By PurpleRose PurpleRose • 08-11-2022
By PurpleRose PurpleRose • 07-11-2022
By sperokesalga sperokesalga • 05-11-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.